Maxion Therapeutics
A UK-based biotech company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases.
Maxion is applying its patented KnotBody technology to generate potent, selective, and long-acting antibody-like drugs.
KnotBody technology combines the benefits of naturally occurring mini-proteins, which have ion channel modulating activity, with antibodies, using phage and mammalian display technologies.
Latest Maxion Therapeutics News & Features
1 February 2024
21 September 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze